ArticleOncotarget2017
Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- The Olive PhenolicCancers · 2025Article
- Article
- Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer.bioRxiv : the preprint server for biology · 2025Article
- An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells.Cancer cell international · 2023Article
- Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.Computational and structural biotechnology journal · 2022Article
- Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.American journal of clinical and experimental urology · 2022Article
- Silencing of SRRM4 suppresses microexon inclusion and promotes tumor growth across cancers.PLoS biology · 2021Article
- Article
- Article
- LIN28B promotes the development of neuroendocrine prostate cancer.The Journal of clinical investigation · 2020Article
- Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.Neoplasia (New York, N.Y.) · 2020Article
- Review
- Differential Tick Salivary Protein Profiles and Human Immune Responses to Lone Star Ticks (Frontiers in immunology · 2019Article
- Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.Cancer science · 2019Article
- "Splice" a way towards neuroendocrine prostate cancer.EBioMedicine · 2018Article
- A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.EBioMedicine · 2018Article
- The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.GigaScience · 2018Article
- Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.EBioMedicine · 2018Article
- Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.Frontiers in oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine prostate cancer (NEPC) is becoming more prevalent as more potent androgen receptor (AR) pathway inhibitors are applied to patients with metastatic tumors. However, there are limited cell and xenograft models currently available, hindering the investigation of signal pathways involved in regulating NEPC progression and the design of high throughput screening assays for inhibitors to treat NEPC patients. Here, we report an NEPC model, LnNE, that is derived from prostate adenocarcinoma cells and has global similarity in transcription and RNA splicing to tumors from NEPC patients. LnNE xenografts are castrate-resistant and highly aggressive. Its tumor take is ∼3-5 weeks and tumor doubling time is ∼2-3 weeks. LnNE expresses multiple neuroendocrine markers, preserves AR expression, but is PSA negative. Its neuroendocrine phenotype cannot be reversed by androgen treatment. LnNE cells grow as multi-cellular spheroids under 2-dimensional culture conditions similar to the NEPC cell line NCI-H660, but have higher proliferation rate and are easier to be transfected. LnNE cells can also adapt to 3-dimensional culture conditions in a 96-plate format, allowing high throughput screening assays. In summary, the LnNE model is useful to study the mechanisms of NEPC progression and to discover potential therapies for NEPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.